TWI851552B - 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 - Google Patents

磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 Download PDF

Info

Publication number
TWI851552B
TWI851552B TW108105041A TW108105041A TWI851552B TW I851552 B TWI851552 B TW I851552B TW 108105041 A TW108105041 A TW 108105041A TW 108105041 A TW108105041 A TW 108105041A TW I851552 B TWI851552 B TW I851552B
Authority
TW
Taiwan
Prior art keywords
antibody
gpc3
drug
seq
heavy chain
Prior art date
Application number
TW108105041A
Other languages
English (en)
Chinese (zh)
Other versions
TW201938587A (zh
Inventor
特拉維斯 碧琪兒
威廉斯 亞瑟
派翠克 布魯克
蘿莉 維思登朵芙
Original Assignee
美商思進公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商思進公司 filed Critical 美商思進公司
Publication of TW201938587A publication Critical patent/TW201938587A/zh
Application granted granted Critical
Publication of TWI851552B publication Critical patent/TWI851552B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW108105041A 2018-02-15 2019-02-15 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 TWI851552B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862631353P 2018-02-15 2018-02-15
US62/631,353 2018-02-15

Publications (2)

Publication Number Publication Date
TW201938587A TW201938587A (zh) 2019-10-01
TWI851552B true TWI851552B (zh) 2024-08-11

Family

ID=67620075

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108105041A TWI851552B (zh) 2018-02-15 2019-02-15 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物

Country Status (13)

Country Link
US (2) US11819553B2 (https=)
EP (1) EP3752534A4 (https=)
JP (2) JP7402807B2 (https=)
KR (1) KR20200121317A (https=)
CN (1) CN111712520A (https=)
AR (1) AR114112A1 (https=)
AU (1) AU2019220700A1 (https=)
CA (1) CA3090251A1 (https=)
IL (1) IL276514B2 (https=)
MX (1) MX2020008030A (https=)
SG (1) SG11202007073SA (https=)
TW (1) TWI851552B (https=)
WO (1) WO2019161174A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019001302A (es) 2016-08-09 2019-06-12 Seattle Genetics Inc Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
AR114112A1 (es) 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
CA3170023A1 (en) * 2020-02-27 2021-09-02 Nanjing Legend Biotech Co., Ltd. Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof
WO2021207701A1 (en) 2020-04-10 2021-10-14 Seagen Inc. Charge variant linkers
EP4146702A4 (en) * 2020-05-07 2024-07-10 Phanes Therapeutics, Inc. Anti-tumor associated antigen antibodies and uses thereof
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
CN112921005B (zh) * 2021-04-14 2023-07-07 中国农业科学院兰州兽医研究所 一株杂交瘤细胞株及其产生的犬细小病毒vp2蛋白单克隆抗体和应用
CA3221398A1 (en) 2021-05-28 2022-12-01 Seagen Inc. Anthracycline antibody conjugates
IL310866A (en) * 2021-08-19 2024-04-01 Adicet Therapeutics Inc Methods for the detection of membrane-bound glypican-3
WO2023045151A1 (en) * 2021-09-24 2023-03-30 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against gpc3 and uses thereof
IL315508A (en) 2022-03-17 2024-11-01 Seagen Inc Camptothecin conjugates
WO2023207475A1 (zh) * 2022-04-24 2023-11-02 昱言科技(北京)有限公司 靶向gpc3的单克隆抗体和包含此抗体的抗体药物缀合物
CN119894536A (zh) * 2022-09-22 2025-04-25 乐普生物科技股份有限公司 Gpc3抗体药物偶联物及其应用
CN119968398A (zh) * 2022-11-28 2025-05-09 四川科伦博泰生物医药股份有限公司 靶向gpc3的抗体及其用途
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
CN119424671A (zh) * 2023-08-01 2025-02-14 上海新理念生物医药科技有限公司 含糖基吡啶型连接子的抗体药物偶联物
WO2025090774A1 (en) 2023-10-24 2025-05-01 Seagen Inc. Chemotherapeutic compounds and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106414499A (zh) * 2014-05-22 2017-02-15 基因泰克公司 抗gpc3抗体和免疫偶联物
TW201739472A (zh) * 2016-05-10 2017-11-16 必治妥美雅史谷比公司 抗磷脂醯肌醇蛋白聚糖-3抗體及妥布賴森(tubulysin)類似物之抗體藥物結合物、製備及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
CA2451493C (en) 2001-06-22 2016-08-23 Chugai Seiyaku Kabushiki Kaisha Cell growth inhibitors containing anti-glypican 3 antibody
WO2004022597A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
CN1842540B (zh) * 2004-07-09 2012-07-04 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
BR112012012912A2 (pt) 2009-11-30 2016-10-25 Biotest Ag anticorpo ou fragmento do mesmo, ácido nucleico, vetor, célula hospedeira, método para a produção de um anticorpo ou um fragmento do mesmo, composição farmacêutica, método para tratar ou prevenir uma condição médica em um indivíduo, uso de um anticorpo ou fragmento do mesmo e métodos in vitro para neutralizar il-10 em uma amostra e para detectar a presença de il-10 em uma amostra.
CN113933504A (zh) * 2014-05-08 2022-01-14 中外制药株式会社 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂
EP2963057A1 (en) 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
SI3900742T1 (sl) * 2014-09-11 2024-10-30 Seagen Inc. Ciljana dostava zdravilnih snovi, ki vsebujejo terciarne amine
WO2017181109A1 (en) * 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof
AR114112A1 (es) 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106414499A (zh) * 2014-05-22 2017-02-15 基因泰克公司 抗gpc3抗体和免疫偶联物
TW201739472A (zh) * 2016-05-10 2017-11-16 必治妥美雅史谷比公司 抗磷脂醯肌醇蛋白聚糖-3抗體及妥布賴森(tubulysin)類似物之抗體藥物結合物、製備及用途

Also Published As

Publication number Publication date
CA3090251A1 (en) 2019-08-22
IL276514B2 (en) 2024-12-01
US20240173427A1 (en) 2024-05-30
JP7402807B2 (ja) 2023-12-21
AU2019220700A1 (en) 2020-09-24
TW201938587A (zh) 2019-10-01
SG11202007073SA (en) 2020-08-28
US20210361776A1 (en) 2021-11-25
JP2021513844A (ja) 2021-06-03
CN111712520A (zh) 2020-09-25
US11819553B2 (en) 2023-11-21
IL276514A (en) 2020-09-30
AR114112A1 (es) 2020-07-22
JP2023089195A (ja) 2023-06-27
IL276514B1 (en) 2024-08-01
EP3752534A1 (en) 2020-12-23
MX2020008030A (es) 2020-09-10
KR20200121317A (ko) 2020-10-23
WO2019161174A1 (en) 2019-08-22
EP3752534A4 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
TWI851552B (zh) 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物
JP7718816B2 (ja) 抗メソセリン抗体およびその抗体薬物コンジュゲート
US20210128742A1 (en) CD123 Antibodies and Conjugates Thereof
JP2023082096A (ja) エリブリンをベースとする抗体－薬物コンジュゲート及び使用方法
CN104936617B (zh) Cd33抗体及其在治疗癌症中的用途
KR20240082348A (ko) 항체, 이의 항체-약물 접합체 및 이의 용도
EP4087613A1 (en) Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof
JP2026026483A (ja) 標的化デンドリマー複合体
CN107889493A (zh) 抗cd123抗体以及其缀合物和衍生物
JP2026501556A (ja) 抗体薬物複合体
KR20200070254A (ko) 면역접합체에서 메티오닌 산화를 방지하는 방법
CA3226899A1 (en) Methods of using antibody-drug-conjugates
JP2026512687A (ja) ヒト化ｌ１ｃａｍ抗体－薬物複合体
US12419964B2 (en) Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload
TW202543685A (zh) 抗體藥物偶聯物及其製備方法和用途
HK1253305B (en) Anti-cd123 antibodies and conjugates thereof